Skip to Content

Key Facts & Figures

Roche Group

Results 2008

Update on HY-Results

  • Roche reports strong results in a challenging market environment: Group sales up significantly, increasing by 10% in local currencies excluding Tamiflu pandemic sales.
  • Strong organic growth of key products more than outweighs lower Tamiflu pandemic sales. Including Tamiflu pandemic sales, Group sales in local currency rise 6%.
  • Operating profit exceeds last year’s record by 4% in local currencies, reaching 13.9 billion Swiss francs despite increased level of R&D investment.
  • Net income down by 5% in Swiss francs to 10.8 billion Swiss francs, primarily due to the strong Swiss franc, but also to lower net financial income.
  • Core Earnings per share at constant exchange rates 2% above previous year’s record level.

Chart - Pharmaceutical an Diagnostic product sales above CHF 1 Billion

Pharmaceuticals

Results 2008

  • Pharmaceuticals sales advance 10% * — twice the global market growth rate. This is the sixth double-digit increase in as many years.
  • Oncology product sales grow by 15% to 19.7 billion Swiss francs. For the first time, three cancer products achieve sales of over 5 billion Swiss francs.
  • Operating profit margin increases by 0.7 percentage points to 36.2% despite significantly lower Tamiflu pandemic sales and increased investments in the development pipeline.
  • Avastin receives accelerated approval for breast cancer in US; applications for approval in brain cancer filed in US and EU.
  • Actemra/RoActemra approved for rheumatoid arthritis in Japan, EU and Switzerland; additional data will be submitted to US FDA in 2009.
  • Twelve major phase III programmes initiated.
  • Acquisitions of Piramed, Mirus and ARIUS significantly strengthen R&D pipeline with new compounds and technology platforms.

*Excluding Tamiflu pandemic sales.

Diagnostics

Results 2008

  • Divisional sales show double-digit growth, rising 10%.
  • Operating profit margin declines 5.3 percentage points to 12.3%, mostly due to acquisition impacts and strong competition in the US diabetes care market.
  • Integration of Tissue Diagnostics (Ventana) completed; the new business’s performance exceeds expectations.